<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684450</url>
  </required_header>
  <id_info>
    <org_study_id>ICM 07-997</org_study_id>
    <nct_id>NCT00684450</nct_id>
  </id_info>
  <brief_title>Cardiac Surgery: In Vivo Titration of Protamine</brief_title>
  <acronym>Protamine</acronym>
  <official_title>Cardiac Surgery : In Vivo Titration of Protamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Organon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safe use of cardiopulmonary bypass (CPB) requires massive doses of intravenous unfractionated
      heparin. At end-CPB, residual heparin is neutralized with intravenous injection of protamine
      sulfate. This prospective, randomized, controlled study will be conducted in 82 voluntary
      subjects admitted for elective, first intention, cardiac surgery requiring cardiopulmonary
      bypass. Each will be randomly assigned to one of two groups. The control group will be
      submitted to a standard protamine infusion of 1.3mg :100U of the total heparin dose given
      during bypass. The test group will receive an infusion of protamine (over 15 minutes) until
      activated clotting time (ACT) values (determined every 3 minutes) depict a plateau, sign that
      the optimal protamine to heparin ratio has been attained. The investigators hypothesize this
      new in vivo titration method to be as efficient as the standard protocol (adequacy of heparin
      neutralization, % heparin rebound, bleeding, and transfusion), and potentially safer by its
      ability to prevent protamine overdose and its deleterious impact on platelet function.15

      Principal Objective

      Evaluate a new in vivo method of titration of protamine sulfate.

      Secondary Objective

      Evaluate the impact of this method on the adequacy of heparin neutralization by measuring:

        1. platelet count

        2. postoperative bleeding

        3. transfusion exposure a

        4. incidence of heparin rebound
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protamine sulfate is administered to reverse the anticoagulant effects of heparin upon
      completion of cardiopulmonary bypass (CPB). In most cases, protamine is given in amounts
      sufficient to neutralize the total dose of heparin.9 This dose is usually calculated with a
      ratio of 1.3mg protamine for every 100U heparin given.10 In the literature, reported doses of
      intraoperatively administered protamine range from 0 to 8mg per 100U of heparin. Given in
      excess, protamine can, in addition to complement activation and hemodynamic instability,11
      induce platelet dysfunctions.12-16 The latter significantly increases both the cost and
      morbidity of cardiac interventions as it is one of the main causes of postoperative bleeding.
      The optimal protamine/heparin ratio is difficult to individualize for each patient because of
      the great interpatient variability in heparin's metabolism4-7 and of the absence of
      correlation between ACT and heparin's plasma concentration.8 Consumption of heparin may vary
      from 0.01 to 3.86U/Kg per minute during CPB.30 The exact concentration of remaining
      circulating heparin at the end of bypass is not easily obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective heparin neutralization (anti-Xa &lt; 0.3 U/ml)</measure>
    <time_frame>Pre protamine, 15 min post protamine, 3h post protamine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of heparin rebound</measure>
    <time_frame>15 min post protamine and 3 hours post Protamine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood losses after surgery and transfusion requirements</measure>
    <time_frame>discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of the platelet count</measure>
    <time_frame>Pre operate, Pré Protamine, 15 min post Protamine, 3 hours post Protamine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Titration protamine</intervention_name>
    <description>10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Protamine in vivo titration in cardiac surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard administration of protamine</intervention_name>
    <description>1.3 mg of Protamine for 100u héparine</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First intention, elective, cardiac surgery: either Coronary Artery Bypass Graft
             (CABG)or valve repair/replacement.

          -  Patients on preoperative aspirin, clopidogrel or heparin will be included.

        Exclusion Criteria:

          -  Combination of CABG and valve surgery

          -  Second intention cardiac surgery

          -  ASA 5 patients

          -  Pre-existing hemostatic disorder (as evidenced by history)

          -  Pregnancy

          -  PLavix &lt; 5 days before de surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine G Rochon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hattersley PG. ACT in the whole blood. JAMA 1966;196:150-154.</citation>
  </reference>
  <reference>
    <citation>Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978 Sep;26(3):231-40.</citation>
    <PMID>110273</PMID>
  </reference>
  <reference>
    <citation>Babka R, Colby C, El-Etr A, Pifarré R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg. 1977 May;73(5):780-2.</citation>
    <PMID>850438</PMID>
  </reference>
  <reference>
    <citation>McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm. 1979 Aug;7(4):331-54.</citation>
    <PMID>512841</PMID>
  </reference>
  <reference>
    <citation>de Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood. 1982 Dec;60(6):1251-8.</citation>
    <PMID>7139119</PMID>
  </reference>
  <reference>
    <citation>Estes JW, Poulin PF. Pharmocokinetics of heparin. Distribution and elimination. Thromb Diath Haemorrh. 1975 Feb 28;33(1):26-37.</citation>
    <PMID>47194</PMID>
  </reference>
  <reference>
    <citation>Despotis GJ, Levine V, Joiner-Maier D, Joist JH. A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery. Blood Coagul Fibrinolysis. 1997 Oct;8(7):419-30.</citation>
    <PMID>9391723</PMID>
  </reference>
  <reference>
    <citation>Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated coagulation time. Anesth Analg. 1988 May;67(5):469-72.</citation>
    <PMID>3364767</PMID>
  </reference>
  <reference>
    <citation>Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology. 1999 Oct;91(4):1122-51. Review.</citation>
    <PMID>10519514</PMID>
  </reference>
  <reference>
    <citation>Lowary LR, Smith FA, Coyne E, Dunham NW. Comparative neutralization of lung- and mucosal-derived heparin by protamine sulfate using in vitro and in vivo methods. J Pharm Sci. 1971 Apr;60(4):638-40.</citation>
    <PMID>5128383</PMID>
  </reference>
  <reference>
    <citation>Kirklin JK, Chenoweth DE, Naftel DC, Blackstone EH, Kirklin JW, Bitran DD, Curd JG, Reves JG, Samuelson PN. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg. 1986 Feb;41(2):193-9.</citation>
    <PMID>3947172</PMID>
  </reference>
  <reference>
    <citation>Carr ME Jr, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res. 1994 Sep 15;75(6):617-30.</citation>
    <PMID>7831681</PMID>
  </reference>
  <reference>
    <citation>Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med. 1986 May 29;314(22):1446-8.</citation>
    <PMID>3702953</PMID>
  </reference>
  <reference>
    <citation>Miyashita T, Nakajima T, Hayashi Y, Kuro M. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. Am J Hematol. 2000 Jun;64(2):112-5.</citation>
    <PMID>10814990</PMID>
  </reference>
  <reference>
    <citation>Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998 Oct;87(4):781-5.</citation>
    <PMID>9768770</PMID>
  </reference>
  <reference>
    <citation>Shigeta O, Kojima H, Hiramatsu Y, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999 Aug;118(2):354-60.</citation>
    <PMID>10425010</PMID>
  </reference>
  <reference>
    <citation>Berger RL, Ramaswamy K, Ryan TJ. Reduced protamine dosage for heparin neutralization in open-heart operations. Circulation. 1968 Apr;37(4 Suppl):II154-7.</citation>
    <PMID>5646575</PMID>
  </reference>
  <reference>
    <citation>Guffin AV, Dunbar RW, Kaplan JA, Bland JW Jr. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg. 1976 Jan-Feb;55(1):110-3.</citation>
    <PMID>1108703</PMID>
  </reference>
  <reference>
    <citation>Moriau M, Masure R, Hurlet A, Debeys C, Chalant C, Ponlot R, Jaumain P, Servaye-Kestens Y, Ravaux A, Louis A, Goenen M. Haemostasis disorders in open heart surgery with extracorporeal circulation. Importance of the platelet function and the heparin neutralization. Vox Sang. 1977;32(1):41-51.</citation>
    <PMID>841962</PMID>
  </reference>
  <reference>
    <citation>Jobes DR, Schwartz AJ, Ellison N, Andrews R, Ruffini RA, Ruffini JJ. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg. 1981 Feb;31(2):161-6.</citation>
    <PMID>6970019</PMID>
  </reference>
  <reference>
    <citation>Ottesen S, Stormorken H, Hatteland K. The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. Scand J Thorac Cardiovasc Surg. 1984;18(2):123-8.</citation>
    <PMID>6611586</PMID>
  </reference>
  <reference>
    <citation>Keeler JF, Shah MV, Hansbro SD. Protamine--the need to determine the dose. Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass. Anaesthesia. 1991 Nov;46(11):925-8.</citation>
    <PMID>1750591</PMID>
  </reference>
  <reference>
    <citation>Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995 Jul;110(1):36-45.</citation>
    <PMID>7609566</PMID>
  </reference>
  <reference>
    <citation>Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth. 1998 Jan;45(1):10-8.</citation>
    <PMID>9466020</PMID>
  </reference>
  <reference>
    <citation>Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995 Jul;110(1):46-54.</citation>
    <PMID>7609568</PMID>
  </reference>
  <reference>
    <citation>Hardy JF, Bélisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg. 1996 Jul;112(1):154-61.</citation>
    <PMID>8691862</PMID>
  </reference>
  <reference>
    <citation>Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, Triscott M, Brown CW, Mark LJ, Cordell AR. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 1992 Mar;76(3):393-401.</citation>
    <PMID>1539851</PMID>
  </reference>
  <reference>
    <citation>Martin P, Horkay F, Gupta NK, Gebitekin C, Walker DR. Heparin rebound phenomenon--much ado about nothing? Blood Coagul Fibrinolysis. 1992 Apr;3(2):187-91.</citation>
    <PMID>1606290</PMID>
  </reference>
  <reference>
    <citation>Shanberge JN, Murato M, Quattrociocchi-Longe T, van Neste L. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol. 1987 Feb;87(2):210-7.</citation>
    <PMID>3812352</PMID>
  </reference>
  <reference>
    <citation>Mabry CD, Read RC, Thompson BW, Williams GD, White HJ. Identification of heparin resistance during cardiac and vascular surgery. Arch Surg. 1979 Feb;114(2):129-34.</citation>
    <PMID>426618</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>August 24, 2011</last_update_submitted>
  <last_update_submitted_qc>August 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Antoine Rochon</investigator_full_name>
    <investigator_title>M.D. FRCPC</investigator_title>
  </responsible_party>
  <keyword>titration of protamine</keyword>
  <keyword>exact dose</keyword>
  <keyword>protamine</keyword>
  <keyword>neutralize heparin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

